Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-10-26Clinical Trial Update: Deep Learning Model to Predict the Recurrence of Stage IA Invasive Lung Adenocarcinoma After Sub-lobar Resection
A completed clinical trial evaluating a deep learning model to predict recurrence risk after sub-lobar resection in Stage IA invasive lung a…
-
CLINICAL_TRIALS research · 2024-10-26Clinical Trial Update: Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab
Clinical trial update indicates the study examining circulating tumor DNA alterations in non-small cell lung cancer patients treated with pe…
-
EMA withdrawal · 2024-10-24EMA Withdrawn: Onbevzi (bevacizumab) — Samsung Bioepis NL B.V.
The EMA has withdrawn the marketing authorization for Onbevzi (bevacizumab) by Samsung Bioepis NL B.V., across multiple cancer indications. …
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating surgery and/or radiation therapy or standard therapy or clinical observation in previously treated stage I…
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: BT1718 in Patients with Advanced Solid Tumours. [Phase 1, Phase 2]
This clinical trial update reports on BT1718 in patients with advanced solid tumors in Phase 1/2, with the study status completed. Condition…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-10-24Clinical Trial Update: Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG [Phase 2]
A Phase 2 clinical trial is evaluating an imaging radiotracer, [18F]-FARAG, in patients with advanced non-small cell lung cancer undergoing …
-
CLINICAL_TRIALS research · 2024-10-24Clinical Trial Update: Test-retest Evaluation of [18F]F-AraG PET [Phase 2]
A Phase 2 clinical trial evaluating the test-retest reliability of the [18F]F-AraG PET tracer in non-small cell lung cancer is currently rec…
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab with and without radiotherapy in non-small cell lung cancer; results from the completed stud…
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer [Phase 2]
Phase 2 results for tislelizumab in combination with chemotherapy as first-line treatment for locally advanced or metastatic non-small cell …
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: Alvopem® (Pemetrexed) Safety Assessment
Safety data from completed trials of Alvopem (pemetrexed) have been assessed and results are now posted.
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer [Phase 1]
This Phase 1 trial update reports termination of the INBRX-105 in combination with pembrolizumab across multiple solid tumors, including hea…
-
CLINICAL_TRIALS withdrawal · 2024-10-23Clinical Trial Update: Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study [Phase 2]
The REPLACING Study, a Phase 2 trial evaluating robotic bronchoscopy with cone-beam CT and indocyanine green for removing lung lesions in St…
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation [Phase 2]
Phase 2 clinical trial update exploring treatment strategies and survival outcomes for non-small cell lung cancer with oncogenic mutations; …
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge [Phase 2]
A Phase 2 clinical trial evaluating sequencing of osimertinib followed by chemotherapy in EGFR-mutated non-small cell lung cancer, focusing …
-
CLINICAL_TRIALS trial_result · 2024-10-18Clinical Trial Update: FDG PET/CT Radiomics Analyses of Lung Cancer Patients Treated With Immunotherapy
This clinical trial update reports on FDG PET/CT radiomics analyses in non-small cell lung cancer patients treated with immunotherapy in a c…
-
CLINICAL_TRIALS research · 2024-10-18Clinical Trial Update: Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC [Phase 2]
A Phase 2 neoadjuvant trial in resectable stage IIA-IIIB non-small cell lung cancer evaluating Sintilimab (PD-1 inhibitor) plus Anlotinib an…
-
EMA withdrawal · 2024-10-17EMA Withdrawn: Gefitinib Mylan (gefitinib) — Mylan Pharmaceuticals Limited
The European Medicines Agency has withdrawn Gefitinib Mylan (gefitinib) from regulatory authorization. It was indicated for non-small cell l…
-
EMA withdrawal · 2024-10-17EMA Withdrawn: Ciambra (pemetrexed disodium hemipentahydrate) — Menarini International Operations Luxembourg S.A.
EMA withdrew Ciambra (pemetrexed disodium hemipentahydrate) from the European market on 17 August 2022, with indications for non-small cell …
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: Milademetan in Advanced/Metastatic Solid Tumors [Phase 2]
A Phase 2 trial of milademetan in advanced or metastatic solid tumors was terminated, with results posted in October 2024.
-
CLINICAL_TRIALS research · 2024-10-17Clinical Trial Update: Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer [Phase 1, Phase 2]
A Phase 1/Phase 2 trial at Vanderbilt-Ingram Cancer Center is evaluating split-course adaptive radiation therapy with pembrolizumab, with or…
-
CLINICAL_TRIALS research · 2024-10-17Clinical Trial Update: SEgmentectomy Versus Lobectomy in T1C Non-Small Cell Lung Cancer (SELTIC) [NA]
This clinical trial update describes the SELTIC study comparing segmentectomy versus lobectomy for T1C non-small cell lung cancer; the trial…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib [Phase 1]
Phase 1 trial evaluating pembrolizumab in combination with afatinib for non-small cell lung cancer with resistance to erlotinib; the study i…
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) [Phase 2]
Phase 2 neoadjuvant study of Vebreltinib for MET-altered, potentially resectable non-small cell lung cancer (stage IIIA-IIIB, N2); the trial…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib
Post-market surveillance clinical trial evaluating ALK-positive advanced non-small cell lung cancer patients treated with Iruplinalkib; the …
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer [NA]
A clinical trial update describing the safety and efficacy evaluation of BST08 in advanced non-small cell lung cancer, with the study curren…